Anti-interleukin-1α autoantibodies in humans: Characterization, isotype distribution, and receptor-binding inhibition—Higher frequency in Schnitzler's syndrome (urticaria and macroglobulinemia)

Saurat, Jean‐Hilaire; Schifferli, Jürg A.; Steiger, G; Dayer, Jean‐Michel; Didierjean, Liliane

doi:10.1016/0091-6749(91)90335-l

Cited by 103 publications

(58 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Thus, serum IgG directed against TNFa and IL-la have been reported in 0-40% and in 1-30% of normal individuals, respectively, (5,6,9,(20)(21)(22)(23). Recently, IgG specific for IL-6 were found in 15% of sera from Danish blood donors ( 14).…”

Section: Resultsmentioning

confidence: 99%

“…Heat denaturation of 251I-IL-lfI increased only the nonspecific binding, and milk proteins suppressed the binding of the cytokine. From the analyses of individual sera, we and others have not been able to obtain evidence of antibodies of the IgG class directed against nondenatured IL-1I3 (19)(20)(21) (43). Furthermore, monomeric, dimeric, trimeric, and higher polymeric forms have been found when examining TNFa in aqueous solution and biological fluids (44,45).…”

Section: Resultsmentioning

confidence: 99%

“…Different assays have been used to measure these antibodies: Western blotting ( 5-10), competition in RIAs and ELISAs (11)(12)(13)(14), binding in direct ELISAs (8-10, 15, 16), binding of radiolabeled cytokines (12)(13)(14)(17)(18)(19)(20)(21)(22)(23), and biological interfer-ence assays (7,8,10,15,17,(24)(25)(26)(27). However, other serum factors than antibodies may compete in RIAs and ELISAs, and inhibition of biological activities may be caused by many factors apart from neutralizing antibodies to cytokines (28)(29)(30)(31).…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Binding of cytokines to pharmaceutically prepared human immunoglobulin.

Svenson¹,

Hansen²,

Bendtzen³

1993

J. Clin. Invest.

114

View full text Add to dashboard Cite

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Binding of cytokines to pharmaceutically prepared human immunoglobulin.

Svenson¹,

Hansen²,

Bendtzen³

1993

J. Clin. Invest.

114

View full text Add to dashboard Cite

show abstract

“…Specific regulation of IL-1 involves various natural mechanisms including soluble IL-1 receptors, IL-1 receptor antagonist (IL-1Ra) and anti-IL-1 antibodies [3][4][5]. Such natural autoantibodies to IL-1a were detected in the sera of patients with various autoimmune disorders including RA [6][7][8][9][10][11][12]. More recently, neutralizing anti-IL-1a antibodies were found in a subset of patients characterized by an increased proportion of primary Sjögren's syndrome or self-limited inflammatory arthritis, with limited joint inflammation and destruction [13].…”

Section: Introductionmentioning

confidence: 99%

High Levels of Neutralizing Autoantibodies Against IL‐1α are Associated with a Better Prognosis in Chronic Polyarthritis: a Follow‐Up Study

Jouvenne

Fossiez²,

Banchereau³

et al. 1997

Scand J Immunol

View full text Add to dashboard Cite

Neutralizing autoantibodies to interleukin (IL)‐1α were detected in a subset of chronic polyarthritis patients characterized by an increased proportion of patients with primary Sjögren's syndrome or self‐limiting inflammatory arthritis, diseases with a much better prognosis than rheumatoid arthritis (RA). The evolution of anti‐IL‐1α antibody levels was followed over 3 years. Incidence and levels were higher in patients with a benign form of polyarthritis. In these patients levels remained stable or increased over the follow‐up period. In contrast, incidence and levels were lower and some RA patients became negative. Negative correlations were observed between the levels of anti‐IL‐1α antibodies and the clinical and biological indices of disease activity. The relative risk factor of developing RA was 12 in the absence of high anti‐IL‐1α antibody levels and 18.2 when associated with the presence of HLA‐DR4. In conclusion, the presence of anti‐IL‐1α autoantibodies appears to be protective and their detection could represent a marker of good prognosis for destruction.

show abstract

“…The pathogenesis of SS is still unclear. Some authors hypothesized that clinical symptoms are due to an uncontrolled activation of IL 1a, a well known mediator of inflammation (2). Therapy of SS is still matter of debate.…”

Section: Ss Is a Rare Disorder First Reported In 1972 Bymentioning

confidence: 99%

Successful Treatment of Schnitzler's Syndrome with Anakinra after Failure of Rituximab Trial

Cascavilla

Bisceglia

D’Arena

2010

Int J Immunopathol Pharmacol

View full text Add to dashboard Cite

We report a 50-year-old man who presented with a 5-year history of an intermittent widespread pruritic urticarioid rash and fever, fatigue, arthralgia and a monoclonal immunoglobulin-M paraprotein. The patient was initially treated with antihistamines and corticosteroids without the disappearance of symptoms. A skin biopsy from the urticarial rash on the thorax was performed, revealing dermal mononuclear and polymorphonuclear cell infiltrate and normal epidermis. A diagnosis of Schnitzler's syndrome (SS), a rare disorder in which the simultaneous occurrence of monoclonal gammopathy and chronic urticaria is usually observed, was made. After an unsuccessful trial with rituximab at a dosage of 375 mg/sqm weekly for 4 consecutive weeks, the patient was treated with anakinra, an inhibitor of interleukin-la that is thought to be involved in the pathogenesis of the disease, at a dose of 100 mg daily given subcutaneously. He showed a prompt response to the drug and he is still well and symptom-free after 12 months of follow-up. On the basis of both this experience and the review of the literature we conclude that anakinra may be a promising option for the treatment of SS. However, these results need to be confirmed on a larger number of patients.Schnitzler's syndrome (SS) is a rare clinical condition characterized by chronic urticaria and monoclonal IgM gammopathy associated with at least two ofthe following features: intermittent fever, bone pain, arthritis or arthralgia, lymphadenopathy, hepato-or splenomegaly, an acute phase response, abnormal findings in bone morphological investigations (1). To date, about 100 patients with SS have been reported but it is thought that this figure is probably underestimated.Although several hypothesis have been proposed, the pathophysiology ofSS is still unknown. Moreover, treatment of this disorder is difficult and there exists no therapy of choice for SS to date. Several attempts have been made with corticosteroids and immunosuppressive drugs, including thalidomide and rituximab. Recently, anecdotal reports have been published on the successful use of anakinra, an inhibitor of interleukin 1a (lL-1 a). In this regards, we report here on a case of a male patient diagnosed with SS and successfully treated with anakinra. Case reportIn May 2007, a 50-year-old man presented with a 5-year history of an intermittent widespread pruritic urticarioid rash and fever greater than 38°C, 0394-6320 (2010)

show abstract

Anti-interleukin-1α autoantibodies in humans: Characterization, isotype distribution, and receptor-binding inhibition—Higher frequency in Schnitzler's syndrome (urticaria and macroglobulinemia)

Cited by 103 publications

References 17 publications

Binding of cytokines to pharmaceutically prepared human immunoglobulin.

Binding of cytokines to pharmaceutically prepared human immunoglobulin.

High Levels of Neutralizing Autoantibodies Against IL‐1α are Associated with a Better Prognosis in Chronic Polyarthritis: a Follow‐Up Study

Successful Treatment of Schnitzler's Syndrome with Anakinra after Failure of Rituximab Trial

Contact Info

Product

Resources

About